

PROSTATE CANCER BIOMARKERS SIMPLIFIED

COMMERCIAL MARKERS	Prolaris ^{®1-16} <i>Myriad Genetic Laboratories</i>	OncotypeDx ^{®1,17-22} <i>Exact Sciences</i>	Decipher Bx ^{®1,23-30} <i>Decipher Biosciences</i>
Active Surveillance Recommendations (DSM Risk) Repeatedly Proven in Untreated Patients	✓	✗	✗
Multi-Modal Recommendations (Mets Risk) Repeatedly Proven in Treated Patients	✓	✗	✗
Studied in ALL NCCN Risk Categories	✓	✗	✓
Covered by Medicare for ALL NCCN Risk Categories	✓	✗	✓
Includes Clinical and Pathological Features	✓	✓	✗
More Prognostic than Actual Adverse Pathology	✓	✗	✗
Proven to Impact Treatment Decisions	✓	✓	✗

Why Prolaris? Because Every Man Deserves a Better Answer.

REFERENCES:

1. NCCN® Clinical Practice Guidelines in Oncology – Prostate Cancer (V.1.2021. MS-65)
2. Cuzick J, et al. Prognostic value of an RNA expression signature derived from cell cycle proliferation genes in patients with prostate cancer: a retrospective study. *Lancet Oncol* 2011; 12:245– 255.
3. Cuzick J, et al. Prognostic value of a cell cycle progression signature for prostate cancer death in a conservatively managed needle biopsy cohort. *Br J Cancer* 2012; 106:1095–1099.
4. Cuzick J, et al. Validation of an RNA cell cycle progression score for predicting death from prostate cancer in a conservatively managed needle biopsy cohort. *Br J Cancer* 2015; 113:382– 389.
5. Cooperberg MR, et al. Validation of a cell-cycle progression gene panel to improve risk stratification in a contemporary prostatectomy cohort. *J Clin Oncol* 2013; 31:1428–1434.
6. Freedland SJ, et al. Prognostic utility of cell cycle progression score in men with prostate cancer after primary external beam radiation therapy. *Int J Radiat Oncol Biol Phys* 2013; 86:848–853.
7. Bishoff JT, et al. Prognostic utility of the cell cycle progression score generated from biopsy in men treated with prostatectomy. *J Urol* 2014; 192:409–414.
8. Koch, Michael O., et al. Use of the cell cycle progression (CCP) score for predicting systemic disease and response to radiation of biochemical recurrence. *Cancer Biomarkers* 2016; 17.1:83–88.
9. Tosoian J, et al. Prognostic Utility of Biopsy-Derived Cell Cycle Progression Score in Patients with NCCN Low-Risk Prostate Cancer Undergoing Radical Prostatectomy: Implications for Treatment Guidance. *BJU International* 2017; doi:10.1111/bju.13911
10. Lin, D. W., et al. Identification of men with low-risk biopsy-confirmed prostate cancer as candidates for active surveillance. *Urologic Oncology: Seminars and Original Investigations*. 2018; doi:10.1016/j.urolonc.2018.03.011
11. Canter, D. J. et al. Comparison of the Prognostic Utility of the Cell Cycle Progression Score for Predicting Clinical Outcomes in African American and Non-African American Men with Localized Prostate Cancer. *European Urology*. 2018; doi:10.1016/j.eururo.2018.10.028
12. Leon P, et al. (2018). Comparison of cell cycle progression score with two immunohistochemical markers (PTEN and Ki-67) for predicting outcome in prostate cancer after radical prostatectomy. *World Journal of Urology*, 36(9), 1495th ser.
13. Shore, N D., et al. Impact of the cell cycle progression test of physician and patient treatment selection for localized prostate cancer. *The Journal of Urology* 2016;195(3),612-618.
14. Crawford, E D, et al. Cell cycle progression score and treatment decisions in prostate cancer: Results from an ongoing registry. *Current Medical Research and Opinion* 2014;30(6), 1025-1031.
15. Tward JD, et al. Ability of the combined clinical cell-cycle risk score to identify patients that benefit from multi versus single modality therapy in NCCN intermediate and high-risk prostate cancer. *Journal of Clinical Oncology*. 2020;38(6): 346. DOI: 10.1200/JCO.2020.38.6_suppl.346
16. Canter, C et al. Biopsy-delivered cell cycle progression score outperformed pathological upgrading or upstaging in predicting biochemical recurrence after surgery. Poster session presented at: Western AUA; 2018 October 28; Maui, HI
17. Lin, et al. 17-Genomic Prostate Score Test Results in the Canary Prostate Active Surveillance Study (PASS) Cohort. *J Clin Oncol* 2020 Mar 4
18. Brand TC, et al. Patient-specific Meta-analysis of 2 Clinical Validation Studies to Predict Pathologic Outcomes in Prostate Cancer Using the 17-Genomic Prostate Score. *Urology*. 2016; 89:69-75.
19. Klein EA, et al. A 17-gene Assay to Predict Prostate Cancer Aggressiveness in the Context of Gleason Grade Heterogeneity, Tumor Multifocality, and Biopsy Under sampling. 2014; doi:10.1016/j.eururo.2014.05.004
20. Cullen J, et al. A Biopsy-based 17-gene Genomic Prostate Score Predicts Recurrence After Radical Prostatectomy and Adverse Surgical Pathology in a Racially Diverse Population of Men with Clinically Low- and Intermediate-risk Prostate Cancer. 2014; doi:10.1016/j.eururo.2014.11.030
21. Van Den Eeden, SK. et al. A Biopsy-based 17-gene Genomic Prostate Score as a Predictor of Metastases and Prostate Cancer Death in Surgically Treated Men with Clinically Localized Disease. *European Urology*. 2018; doi: 10.1016/j.eururo.2017.09.013.
22. Canfield, S. et al. Active Surveillance Use Among a Low-risk Prostate Cancer Population in a Large US Payer System: 17-Genomic Prostate Score Versus Other Risk Stratification Methods. *Reviews in Urology*. 2017; doi:10.3909/riu0786
23. Berlin, A, et al. Genomic classifier for guiding treatment of intermediate-risk prostate cancers to dose-escalated image guided radiotherapy without hormone therapy. *International Journal of Radiation Oncology, Biology, Physics*. 2018; doi:10.1016/j.ijrobp.2018.08.030
24. Kim, H. L., et al. Validation of the Decipher Test for predicting adverse pathology in candidates for prostate cancer active surveillance. *Prostate Cancer and Prostatic Diseases*. 2018; doi:10.1038/s41391-018-0101-6
25. Klein, E. A., et al. Decipher Genomic Classifier Measured on Prostate Biopsy Predicts Metastasis Risk. *Urology*, 90, 148–152. 2016; doi:10.1016/j.urology.2016.01.012
26. Lee, H. J., et al. Evaluation of a genomic classifier in radical prostatectomy patients with lymph node metastasis. *Research and Reports in Urology*, 8, 77–84. 2016; doi:10.2147/RRU.S99997
27. Nguyen, P. L., et al. Ability of a Genomic Classifier to Predict Metastasis and Prostate Cancer-specific Mortality after Radiation or Surgery based on Needle Biopsy Specimens. *European Urology*, 72(5), 845–852. 2017; doi:10.1016/j.eururo.2017.05.009
28. Nguyen, P. L., et al. Utilization of biopsy-based genomic classifier to predict distant metastasis after definitive radiation and short-course ADT for intermediate and high-risk prostate cancer. *Prostate Cancer and Prostatic Diseases*, 20(2), 186–192. 2017; doi:10.1038/pcan.2016.58
29. Spratt, D. E., et al. Development and validation of a novel integrated clinical-genomic risk group classification for localized prostate cancer. *Journal of Clinical Oncology*, 36(6), 581–590. 2018; doi:10.1200/JCO.2017.74.2940
30. Xu, M. J., et al. Genomic Risk Predicts Molecular Imaging-detected Metastatic Nodal Disease in Prostate Cancer. *European Urology Oncology*. 2018; doi:10.1016/j.euo.2018.11.002

† Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN® Guidelines) for Prostate Cancer V.1.2021. ©2021 National Comprehensive Cancer Network, Inc. 2019. All rights reserved. To view the most recent and complete version of the guideline, go online to NCCN.org. NATIONAL COMPREHENSIVE CANCER NETWORK®, NCCN®, NCCN GUIDELINES®, and all other NCCN content are trademarks owned by the National Comprehensive Cancer Network, Inc.



Myriad Genetic Laboratories, Inc.
www.Polaris.com

